However, KRAS mutations render CRC cells more resistant to CD95L/FasL (ligand of TNF receptor family such as TRAIL) and TRAIL-induced apoptosis, but also convert the respective ligand-induced signals into a migration-activating signal [162]. This evidence concerns the gene KRAS and colorectal carcinoma.